AMG.DE Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 18:35):

Stats
Объем за сегодня	136.00
Средний объем	594.00
Рыночная капитализация	135.19B
EPS	€0 ( 2024-04-24 )
Дата следующего отчета о доходах	( €0 ) 2024-05-01
Last Dividend	€2.13 ( 2023-08-17 )
Next Dividend	€0 ( N/A )
P/E	21.63
ATR14	€0.763 (0.30%)

Amgen Inc Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Amgen Inc Финансовые показатели

Annual	2023
Выручка:	€28.19B
Валовая прибыль:	€19.74B (70.02 %)
EPS:	€12.56

FY	2023
Выручка:	€28.19B
Валовая прибыль:	€19.74B (70.02 %)
EPS:	€12.56

FY	2022
Выручка:	€26.32B
Валовая прибыль:	€19.92B (75.66 %)
EPS:	€12.18

FY	2021
Выручка:	€25.98B
Валовая прибыль:	€19.53B (75.16 %)
EPS:	€9.74

Financial Reports:

No articles found.

Amgen Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€1.940 (N/A)	€1.940 (N/A)	€2.13 (N/A)	€2.13 (N/A)	€2.13 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Amgen Inc Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.55 - Stable (8.94%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.280	2011-08-16
Last Dividend	€2.13	2023-08-17
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	49	--
Total Paid Out	€56.75	--
Avg. Dividend % Per Year	0.00%	--
Score	4.22	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.55
Div. Directional Score	7.43	--

Next Divdend (Est)
(2024-07-01)

€2.17 Estimate 22.19 %

Dividend Stability

0.59 Average

Dividend Score

4.22

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
IE2A.F	Ex Dividend Junior	2023-05-02	Sporadic	0.00%
SOW.DE	Ex Dividend Junior	2023-05-18	Annually	0.00%
CRZK.DE	Ex Dividend Junior	2023-07-17	Annually	0.00%
LLD.DE	Ex Dividend Junior	2023-08-03	Annually	0.00%
1U1.DE	Ex Dividend Junior	2023-05-17	Annually	0.00%
UWS.DE	Ex Dividend Knight	2023-09-07	Quarterly	0.00%
EIN3.DE	Ex Dividend Knight	2023-06-26	Annually	0.00%
NOVC.DE	Ex Dividend Junior	2023-08-18	Semi-Annually	0.00%
ADS.F	Ex Dividend Junior	2023-05-12	Annually	0.00%
GKS.DE	Ex Dividend Junior	2023-06-29	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.238	1.500	5.23	7.85	[0 - 0.5]
returnOnAssetsTTM	0.0691	1.200	7.70	9.23	[0 - 0.3]
returnOnEquityTTM	1.033	1.500	10.00	10.00	[0.1 - 1]
payoutRatioTTM	0.678	-1.000	3.22	-3.22	[0 - 1]
currentRatioTTM	1.649	0.800	6.75	5.40	[1 - 3]
quickRatioTTM	1.027	0.800	8.67	6.93	[0.8 - 2.5]
cashRatioTTM	0.595	1.500	7.81	10.00	[0.2 - 2]
debtRatioTTM	0.665	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	3.15	1.000	9.94	9.94	[3 - 30]
operatingCashFlowPerShareTTM	15.83	2.00	4.72	9.44	[0 - 30]
freeCashFlowPerShareTTM	13.76	2.00	3.12	6.24	[0 - 20]
debtEquityRatioTTM	10.37	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.700	1.000	1.663	1.663	[0.2 - 0.8]
operatingProfitMarginTTM	0.321	1.000	5.57	5.57	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.131	1.000	-0.383	-0.383	[0.2 - 2]
assetTurnoverTTM	0.290	0.800	-1.399	-1.119	[0.5 - 2]
Total Score				10.30

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	21.50	1.000	7.93	0	[1 - 100]
returnOnEquityTTM	1.033	2.50	3.34	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	13.76	2.00	5.41	6.24	[0 - 30]
dividendYielPercentageTTM	3.20	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	15.83	2.00	4.72	9.44	[0 - 30]
payoutRatioTTM	0.678	1.500	3.22	-3.22	[0 - 1]
pegRatioTTM	-5.58	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.300	1.000	4.99	0	[0.1 - 0.5]
Total Score				4.55

Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Обновления в реальном времени для Amgen Inc [AMG.DE]

Upcoming Earnings Alert

Amgen Inc Dividend Information - Ex Dividend Knight

Dividend Commentary

Top 10 dividend Companies for XETRA

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)